Abstract
Extensive researches within the last decade have supported the anti-inflammatory properties of curcumin. However, the development and clinical application of curcumin have been limited significantly by its instability and poor metabolic property resulting from the β-diketone moiety decomposition and phenolic glucuronides. In this paper, a curcumin derivative (A50) without β-diketone and phenolic hydroxyl groups was designed and reported. The X-ray diffraction analysis showed a more rigid structure of A50 than that of curcumin. A pharmacokinetic study of A50 in rats indicated that its metabolic parameters were significantly improved compared to those of curcumin. Furthermore, A50 exhibited stronger anti-inflammatory activity than curcumin did via the mechanism, at least partly, associated with inhibiting ERK and JNK phosphorylation in macrophages. These results suggest that the structural modification is both pharmacokinetically and pharmacologically beneficial, and A50 may be a promising anti-inflammatory candidate to treat various inflammatory diseases.
Keywords: Anti-inflammatory property, Curcumin, Crystal structure, (2E, 5E)-2, 5-bis(2, 5-dimethylbenzylidene) cyclopentanone, Mono-carbonyl analogue of curcumin, Pharmacokinetic profile.
Letters in Drug Design & Discovery
Title:Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Volume: 10 Issue: 6
Author(s): Xiangjian Chen, Luqing Ren, Xiuhua Zhang, Lu Guo, Jianmin Zhou, Guang Liang and Yi Wang
Affiliation:
Keywords: Anti-inflammatory property, Curcumin, Crystal structure, (2E, 5E)-2, 5-bis(2, 5-dimethylbenzylidene) cyclopentanone, Mono-carbonyl analogue of curcumin, Pharmacokinetic profile.
Abstract: Extensive researches within the last decade have supported the anti-inflammatory properties of curcumin. However, the development and clinical application of curcumin have been limited significantly by its instability and poor metabolic property resulting from the β-diketone moiety decomposition and phenolic glucuronides. In this paper, a curcumin derivative (A50) without β-diketone and phenolic hydroxyl groups was designed and reported. The X-ray diffraction analysis showed a more rigid structure of A50 than that of curcumin. A pharmacokinetic study of A50 in rats indicated that its metabolic parameters were significantly improved compared to those of curcumin. Furthermore, A50 exhibited stronger anti-inflammatory activity than curcumin did via the mechanism, at least partly, associated with inhibiting ERK and JNK phosphorylation in macrophages. These results suggest that the structural modification is both pharmacokinetically and pharmacologically beneficial, and A50 may be a promising anti-inflammatory candidate to treat various inflammatory diseases.
Export Options
About this article
Cite this article as:
Chen Xiangjian, Ren Luqing, Zhang Xiuhua, Guo Lu, Zhou Jianmin, Liang Guang and Wang Yi, Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50, Letters in Drug Design & Discovery 2013; 10 (6) . https://dx.doi.org/10.2174/1570180811310060010
DOI https://dx.doi.org/10.2174/1570180811310060010 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Molecular Pathogenesis of Non Muscle-Invasive Bladder Cancer: Implications for Novel Targeted Therapies
Current Molecular Medicine Myeloperoxidase as a Target for the Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors
Current Medicinal Chemistry Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
Current Radiopharmaceuticals Gene Therapy of Chronic Pain
Current Gene Therapy Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science A Closer Look at α-Secretase
Current Alzheimer Research Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Probiotics: From Functional Foods to Pharmaceutical Products
Current Pharmaceutical Biotechnology Lactobacillus GG (LGG) Peptides Can Inhibit Antibiotic-Resistant Bacteria Growth
Anti-Infective Agents in Medicinal Chemistry Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology